Most healthtech fundraising advice is written for a market that no longer exists. It tells founders to build a compelling deck, identify a large TAM, and find investors who share their vision. That advice was survivable in 2019. It gets you politely passed on in 2026.

Here is the sequence that is actually working right now, built from the data on where the capital in this cycle is concentrating and what it is buying.

Step one: build the evidence before you build the deck

Rock Health's H1 2026 data and CB Insights' Q2 2026 report both point to the same underlying condition: deal counts are down, checks are bigger, and capital is going to companies that have already de-risked the commercial question before the first investor meeting. That means the highest-leverage use of your pre-raise time is not deck design. It is landing and instrumenting one real contract with usage data behind it.

Specifically, before you start investor meetings, you want:

  1. A signed, paying contract, not a pilot MOU.
  2. At least one renewal cycle or expansion event inside that account, or a clear leading indicator of one.
  3. A repeatable version of the sales process that got you there, so the next three logos do not each require a bespoke founder-led negotiation.
  4. A clean investor-ready dashboard that already tracks the metrics diligence will ask for, built before diligence starts, not assembled in response to a request. High Rock's breakdown of what a Series A diligence team actually expects on day one is worth reading before you build yours.

Step two: know which comp set you actually belong to

Do not let an investor benchmark you against the wrong comp set by accident. Yanne Capital's data on healthcare AI multiples shows a 9.2x median forward ARR multiple for AI healthcare rounds against 4.5x for non-AI healthtech in the same period. If you are a non-AI company being informally compared to AI comps, or an AI company with a thin data moat being compared to a platform with proprietary clinical data, you will either underprice yourself or set an expectation you cannot defend in diligence. Walk into the first meeting with your own comp table, sourced from real data, not from press coverage of the largest rounds in the category.

Step three: sequence your investor types deliberately

Different capital sources want different things, and running them in the wrong order wastes your best evidence on the wrong audience:

  • Specialist healthcare VCs want the sharpest version of your commercial evidence and a clear answer to why an incumbent cannot build this in 18 months.
  • Payer or health system strategic venture arms, like Cigna Group Ventures or the Blue Venture Fund, want alignment with a cost or utilization problem they already have, and a plausible path to a real commercial pilot inside their own book, negotiated as a separate contract from the equity check.
  • Generalist and crossover funds are pricing you against a combined biotech and digital health portfolio and will apply a more rigorous evidence standard to any clinical claim than a pure software investor would.
  • Growth investors writing the mega-round checks that are increasingly carrying the market's aggregate funding number want proof the unit economics hold at three times your current scale, not just proof they hold today.

Approach specialist healthcare investors first, while your pitch and metrics are sharpest, use their feedback to tighten the story, then bring in strategics and generalists once the round has real momentum and term sheet language to react to.

Step four: negotiate strategic checks on separate terms from the commercial relationship

If a payer or health system strategic joins the round, get the commercial agreement in writing as an independent contract, not a verbal promise bundled into the equity terms. This single negotiation point determines whether a strategic investor's check becomes a genuine growth accelerant or a line item that chills your ability to sell to their competitors later.

Step five: price the round against a market that is not distributing capital evenly

With deal counts at a decade low and dilution falling for the deals that do close, per Carta's Q1 2026 data, the founders getting favorable terms are the ones who do not need the capital badly enough to accept a bad price. Extend your runway before you start the process so that you are raising from strength, not from a deadline the other side of the table can see.

The takeaway

The 2026 healthtech fundraising market punishes a good narrative with no contract behind it and rewards a company that has already proven the commercial thesis at a small scale. Build the proof first. The deck is the last five percent of the work, not the first.